Evotec earns US$40m in global licence deal with BMS
German CRO Evotec SE enters licence agreement Bristol Myers Squibb within its neuroscience partnership providing US$40m upfront, milestones and double-digit sales royalities.
ADVERTISEMENT
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 1996 entries already.
Entries by Thomas Gabrielczyk
Nanobiotix SA licences NBTXR3 to J&J
Paris-based Nanobiotix SA has signed a potential US$1.8bn oncology deal with Janssen Pharmaceutica NV for the global commercialisation rights of its radioenhancer NBTXR3.
Living therapy: Microbial immunotherapy of Exeliom Biosciences gets a boost
Exeliom Biosciences, a French company focused on the microbiome-immunomodulation axis to develop next-generation immunotherapies, has announced the closing of its €24m (US$26m) Series A financing to advance the clinical development of its therapeutic pipeline, including several clinical trials of EXL01, a novel bacterial immunotherapy with applications in cancer and infectious diseases.
Dutch go first: pre-approval tastings of cultivated meat & seafood in the Netherlands
It is just announced that it will soon be possible to taste farmed meat and seafood in the Netherlands under controlled conditions. The Dutch government, in collaboration with cultured meat producers Meatable and Mosa Meat, and industry representative HollandBIO, has successfully developed a ‘code of practice’ that will allow tastings in controlled environments.
EU Regulation of Genome Editing in Plants not yet a law
A long-awaited draft regulation from the EU Commission’s DG Sante to deregulate the authorisation, risk assessment and labelling of a whole range of new genetically modified organisms (GMOs) has been published today by the College of the Commission. New Genomic Techniques (NGT) are introduced as an umbrella term for certain genetic engineering techniques that aim to modify DNA more precisely than "old" methods by targeting changes to pre-defined loci in the genome. The proposal creates two distinct pathways for NGT plants to be placed on the market. "Category 1 NGTs" are considered equivalent to conventionally bred plants and no longer require prior case-by-case risk assessment.
Dutch NLC has €20m in first close of new Health Impact Fund
Dutch venture builder NLC has announced a €20m first close for its new Health Impact Fund, from which it will invest in 40 startups, both new investments and follow-on. It’s targeting a final close of €100m later this year.
Biosimilars climb the alps
Generic and biosimilar manufacturer Sandoz is expanding with a new biologics production facility in Lendava, Slovenia to prepare for more demand in Europe for biosimilar products.
Sweden: Biobank law
The Sweden Biobank Act governs the collection, storage, and usage of identifiable human material samples for specific purposes.
Cell & Gene Therapies: time for celebration?
Six years after the first approved cell and gene therapy, the field is living a renaissance. 5 additional FDA-approved therapies were added in 2022 and could be doubled in 2023, setting a new pace to cell & gene therapies. The BioRN Annual Conference on September 29th in Heidelberg will highlight next-generation approaches in the field.
Cell & Gene Therapies: time for celebration?
Six years after the first approved cell and gene therapy, the field is living a renaissance. 5 additional FDA-approved therapies were added in 2022 and could be doubled in 2023, setting a new pace to cell & gene therapies. The BioRN Annual Conference on September 29th in Heidelberg will highlight next-generation approaches in the field.